Replies to post #75235 on PharmaCyte Biotech Inc (PMCB)

[Edward]

Correct. PMCB value is their primary business. Primary business is the commercialization of treatments for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology, Cell-in-a-Box. The Cell-in-a-Box technology is used as a platform for several types of cancer, including advanced, inoperable pancreatic cancer, and diabetes.
Presenting the investment in Austrianova on an equity basis should not have any effect on the market cap of PMCB. Their success in the clinical trials (hopefully)for CIAB will have an effect on the market cap.

[concordia]

Sure and PMCB is paying Austrianova 150k a month because Austrianova is flush with cash. PMCB its seems every years is sending a $million or so across the Atlantic to keep them in business. IMHO